UK laboratory research reference on tirzepatide weight-loss timeline: SURMOUNT-1 week-by-week data, dose-response across 5/10/15 mg, SURMOUNT-4 withdrawal, SURMOUNT-3 with IBT, body composition and protocol design. 2026.
UK laboratory research reference on semaglutide weight-loss timeline: STEP-1 week-by-week data, STEP-5 104-week long-term, STEP-4 withdrawal effects, dose-response, and protocol design considerations. 2026 research-grade reference.
UK laboratory research reference on GHK-Cu (copper tripeptide-1): mechanism of action, gene expression effects, wound-healing and skin research, hair-follicle studies, topical vs subcutaneous protocols, and UK research-grade sourcing. 2026 reference.
UK laboratory research reference on sermorelin: the unmodified GHRH(1-29) parent molecule, receptor pharmacology, paediatric Geref trial history, pulsatility preservation, comparison with CJC-1295 and tesamorelin, and modern research protocol design. 2026.
UK laboratory research reference on tesamorelin: stabilised GHRH analogue, approved indication in HIV lipodystrophy, visceral fat reduction data, MASLD research, pharmacokinetics and protocol design. 2026 research-grade reference.
UK laboratory research reference on MK-677 (ibutamoren): oral ghrelin-receptor agonism, pharmacokinetics, IGF-1 dose-response, long-term safety data, and study protocol design. Research-grade reference, 2026.
UK laboratory research reference on CJC-1295 (with or without DAC) and ipamorelin: receptor pharmacology, combined-stack rationale, dose-response data, reconstitution and protocol design. 2026 research-grade reference.
UK laboratory research reference on GLP-1 receptor agonists in MASLD and MASH: SYNERGY-NASH tirzepatide data, ESSENCE semaglutide data, retatrutide hepatic results, MRI-PDFF and histology endpoints, protocol design. 2026.
Comprehensive UK laboratory research reference on GLP-1 receptor agonist side effects: mechanism of GI adverse events, class-level signals, pancreatitis, gallbladder and thyroid signals, and research-protocol mitigation strategies. 2026 update.
Head-to-head laboratory research reference comparing tirzepatide (GLP-1/GIP dual agonist) to semaglutide (GLP-1 mono-agonist): SURMOUNT-5 data, receptor pharmacology, cardiometabolic endpoints and protocol design. UK research-grade, 2026.
Head-to-head laboratory research reference comparing liraglutide and semaglutide: STEP-8 and SUSTAIN-10 data, receptor pharmacology, half-life, dosing cadence and study protocol considerations. UK research-grade reference, 2026.
A 2026 UK research reference for semaglutide — the GLP-1 receptor agonist behind STEP (obesity), SUSTAIN (T2DM), SELECT (cardiovascular outcomes), and FLOW (diabetic kidney disease). Mechanism, clinical evidence summary, protocol…
